Algernon Health Inc. (CSE:AGN)
Canada
· Delayed Price · Currency is CAD 0.0400
0.00 (0.00%)
Mar 9, 2026, 2:02 PM EST
Algernon Health Company Description
Algernon Health Inc. operates as a clinical stage pharmaceutical development company in Canada and Australia.
The company focuses on developing the therapeutic drugs in the areas of non-alcoholic steatohepatitis, liver disease, chronic kidney disease, and stroke program.
Its pipeline includes repirinast for the treatment of chronic kidney disease; and N,N-Dimethyltryptamine for the treatment of strokes and traumatic brain injuries.
The company was formerly known as Algernon Pharmaceuticals Inc. and changed its name to Algernon Health Inc. in October 2025.
Algernon Health Inc. was incorporated in 2015 and is headquartered in Vancouver, Canada.
Algernon Health Inc.
| Country | Canada |
| Founded | 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Christopher Moreau |
Contact Details
Address: 601 West Broadway Vancouver, BC V5Z 4C2 Canada | |
| Phone | 604 398 4175 |
| Website | algernonhealth.com |
Stock Details
| Ticker Symbol | AGN |
| Exchange | Canadian Securities Exchange |
| Fiscal Year | September - August |
| Reporting Currency | CAD |
| ISIN Number | CA01559C1068 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Christopher J. Moreau | Chief Executive Officer and Director |
| James F. Kinley C.A., CPA | Chief Financial Officer and Corporate Secretary |
| Dr. Christopher Bryan Ph.D. | Vice President of Research and Operations |